Autres langues Knight Therapeutics Inc. BOERSE MUENCHEN

Actions

04K

CA4990531069

Marché Fermé - BOERSE MUENCHEN Autres places de cotation 21:44:26 28/06/2024			Varia. 5j.	Varia. 1 janv.
3,9 ^EUR	+2,09 %		+5,98 %	+8,94 %

09/05	Knight Therapeutics en hausse de près de 3% après l'annonce d'un accord d'approvisionnement et de distribution pour un médicament contre le TDAH ; malgré un T1 mitigé	MT
09/05	Transcript : Knight Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Knight Therapeutics Up Near 3% After Announcing Supply and Distribution Agreement For ADHD Medication; Despite Mixed Q1	09/05
Knight Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Knight Therapeutics Brief: Q1 Net loss was $4.546 Million; Revenues were $86.604 Million	09/05
Knight Therapeutics Brief: Entering into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM In Canada and Latin America	09/05
Knight Therapeutics Reports First Quarter 2024 Results	09/05
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin America	09/05
Knight Therapeutics Inc. Reconfirms Earnings Guidance for the Year 2024	09/05
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for Jornay Pm® for Canada and Latin America	09/05
Knight Therapeutics Inc. announces voting results from the Annual General Meeting	09/05
Knight Therapeutics Inc. announces voting results from the Annual General Meeting	09/05
Knight to Present at the 2024 RBC Capital Markets Global Healthcare Conference in New York City	07/05
Notice of Knight Therapeutics' First Quarter 2024 Results Conference Call	02/05
Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	09/04
Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity	28/03
Knight Therapeutics Reports Fourth Quarter Results	21/03
Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2024	21/03
Knight Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Knight Therapeutics Inc. Announces Impairment Charges for the Fourth Quarter of 2023	21/03
Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results	21/03
Knight Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	21/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Knight Therapeutics Inc. BOERSE MUENCHEN

Actions

04K

CA4990531069

Autres langues

Filtres